Abstract

Stem cell transplantation therapies are currently under investigation for central nervous system disorders. Although preclinical models show benefit, clinical translation is somewhat limited by the absence of reliable noninvasive methods to confirm targeting and monitor transplanted cells in vivo. Here, we assess a novel magnetic resonance imaging (MRI) contrast agent derived from magnetotactic bacteria, magneto-endosymbionts (MEs), as a translatable methodology for in vivo tracking of stem cells after intracranial transplantation. We show that ME labeling provides robust MRI contrast without impairment of cell viability or other important therapeutic features. Labeled cells were visualized immediately post-transplantation and over time by serial MRI in nonhuman primate and mouse brain. Postmortem tissue analysis confirmed on-target graft location, and linear correlations were observed between MRI signal, cell engraftment, and tissue ME levels, suggesting that MEs may be useful for determining graft survival or rejection. Overall, these findings indicate that MEs
cell transplantation, cellular therapy, in vivo tracking, nervous system, stem cell transplantation, stem/progenitor cell

1 | INTRODUCTION

Cell-based therapies provide a multifaceted approach for the treatment of central nervous system (CNS) disorders. Intracranial transplantation of multiple cell types is effective in animal disease models and is currently under clinical investigation for stroke, Parkinson's disease, and Alzheimer's disease. We are currently developing a line of human neural stem cells (hNSCs) as a novel therapy for Alzheimer’s disease. Our work, and that of others, shows the benefit of cell transplantation in preclinical disease models and demonstrates the safety and feasibility of targeted intracranial delivery. However, preclinical development and translation to patients is limited by ineffective methods to assess graft delivery and post-transplantation graft survival in vivo. Real-time information on targeting accuracy, biodistribution, and engraftment is critical to determining efficacy and developing effective targeted therapies. Assessing these parameters in vivo in a noninvasive manner is particularly important in the efficacious and ethical use of large animal models.

Various imaging modalities have been used to monitor cells in vivo, including optical and bioluminescence imaging, positron emission tomography, and magnetic resonance imaging (MRI). MRI is often the modality of choice as it avoids ionizing radiation and offers 3D imaging capacity, excellent soft tissue contrast particularly in the CNS, and high resolution. In vivo tracking by MRI requires either genetic modification or direct cell labeling with contrast agents. Superparamagnetic iron oxide (SPIO) nanoparticles are the most commonly used exogenous contrast agent for cell tracking and several are FDA-approved, but broad clinical use has been limited to immediate confirmation of cell transplantation. MR signal can significantly decrease over time as SPIO is diluted in dividing cells, and nonspecific particle uptake by endogenous tissue and cells has been reported. Furthermore, MR signal does not always correlate with graft cell viability, as in vivo SPIO contrast signal persists after transplanted cell death. These limitations have made it difficult to longitudinally assess transplanted cells in long-term studies.

The recent development of novel magneto-endosymbiont (ME) contrast agents from magnetotactic bacteria may overcome many of these challenges. MEs are derived from the nonpathogenic bacterial strain Magnetospirillum magneticum AMB-1, and naturally synthesize multiple chains of membrane-enclosed magnetite particles, known as magnetosomes. Due to their high relaxivity, MEs are robust contrast agents for T2-weighted MRI imaging. ME labeling of eukaryotic cells was recently shown to be an effective in vivo MRI tracking method, and a unique live-cell specificity feature was demonstrated in a murine myocardial infarction model. However, ME-based tracking technology has not yet been examined in immunocompetent animals or large animal models after targeted intracranial transplantation.

Therefore, the purpose of this study was to evaluate ME-based cell tracking in two immunocompetent xenotransplantation models, and characterize the impact of labeling on neural cell function in vitro and in vivo. In this report, we transplanted ME-labeled hNSCs (hNSC-Mag) via targeted intracranial injection into the non-human primate (NHP) and mouse brain to determine the translational potential of this novel MRI contrast agent.

2 | MATERIALS AND METHODS

2.1 | ME labeling

hNSCs (line HK532-CAG-IGF1) were supplied by Neuralstem, Inc. (Germantown, MD) and cultured as previously described. ME labeling was performed using Magnelle reagents per manufacturer protocols (Bell Biosystems, San Francisco, CA) and published reports. Briefly, MEs were added to cells at 60% to 70% confluence in antibiotic-free growth medium and incubated for approximately 16 hours in normal culture conditions (5% O2, 5% CO2, 37°C). Cells were then washed three times in growth media and treated with...
2.2 | In vitro characterization

2.2.1 | Differentiation potential

Cells were differentiated for 7 days on glass coverslips and standard immunocytochemistry was performed using primary antibodies for differentiation markers: TUJ1 (CH23005, Neuromics, Edina, MN), MAP2 (MAB3418, Millipore), glial fibrillary acidic protein (GFAP) (Z0334, Dako Corporation, Carpinteria, California), and OLG2 (Ab9610, Millipore).

2.2.2 | Proliferation and migration

Proliferation and migration were measured using commercially available kits as previously described. For proliferation, cells on glass coverslips (on day 0 or day 7 during differentiation) were incubated with 10 μM 5’-ethynyl-2’-deoxyuridine (EdU) for 2 hours before fixation and processing following manufacturer protocols for the Click-it EdU kit (Thermo Fisher Scientific). For migration assessment, migration inserts containing cells at day 0 or day 7 of differentiation were placed into growth media plus 10% serum. After 24 hours, cells that had migrated through the insert were stained and quantified according to manufacturer protocols for the Click-It EdU kit (Thermo Fisher Scientific). For migration assessment, migration inserts containing cells at day 0 or day 7 of differentiation were placed into growth media plus 10% serum. After 24 hours, cells that had migrated through the insert were stained and quantified according to manufacturer protocols for the Click-It EdU kit (Thermo Fisher Scientific).

2.2.3 | Neurotrophic factor production

Neurotrophic factors were measured in conditioned media from undifferentiated and differentiated cells using enzyme-linked immunosorbent assays for human-specific insulin-like growth factor 1 (IGF1; R&D Systems, Minneapolis, Minnesota), brain-derived neurotrophic factor (BDNF; Raybiotech, Norcross, Georgia), and vascular endothelial growth factor (VEGF; Raybiotech).

2.2.4 | Neuroprotection

Neuroprotective capacity of hNSC was assessed using an established amyloid beta toxicity assay in primary embryonic cortical neurons cocultured with or without hNSC.

2.3 | NHP transplantation and MRI

All animal protocols were approved by the University of Michigan Institutional Animal Care and Use Committee, and performed according to University of Michigan guidelines and state and federal regulations. Intracranial transplantation was performed on a 14-year-old healthy female rhesus macaque (Macaca mulatta) weighing 9.9 kg as previously described. Briefly, stereotactic surgical coordinates were obtained for the hippocampus, thalamus, and posterior cingulate using a rhesus macaque atlas. Cell suspensions were prepared at 80 k/μL in hibernation medium (Neuralstem, Inc.), and Trypan Blue exclusion testing ensured transplantation of >90% viable cells. Injections were performed using an intracerebral microinjection device with a 25G needle (FHC, Inc., Bowdoin, Maine), a 50 μL syringe barrel (Hamilton Co., Reno, Nevada), and a PHD 22/2000 syringe pump (10 μL/min; Harvard Apparatus, Holliston, Massachusetts). hNSC-Mag were administered to the temporal lobe, thalamus, and posterior cingulate on the left side (2 x 20 μL/site), and unlabeled hNSCs to the contralateral temporal lobe target (1 x 20 μL). An immunosuppressive regimen, based on previous clinical trials transplanting human stem cells, was adapted and administered as follows. One day prior to surgery, Tacrolimus (FK506) was administered per os (PO) in food (4.25 mg/kg, BID). Post-transplantation, PO medications were administered as follows: postoperative day (POD) 2, 5; 42 mg FK506, 9 mg prednisone, 140 mg mycophenolate mofetil; POD 7, 9; 40 mg FK506, 6 mg prednisone, 250 mg mycophenolate mofetil; POD 12: 40 mg FK506, 6 mg prednisone; POD 14, 16; 40 mg FK506, 6 mg prednisone, 250 mg mycophenolate mofetil; POD 19, 21: 40 mg FK506, 3 mg prednisone, 250 mg mycophenolate mofetil; POD 23; 45 mg FK506, 3 mg prednisone, 250 mg mycophenolate mofetil. The NHP was monitored daily for neurological sequelae (eg, level of arousal, paresis, incoordination) and wound healing. Plasma FK506 was assessed by peripheral blood draw at various postoperative time points. MR images were obtained on a GE SIGNA MR750 3.0 Tesla system with an 8-channel HR Brain Array head coil (GE Healthcare, Waukesha, Wisconsin), 1 month preoperatively, and at POD 7, 14, and 28. The NHP was anesthetized with 4 to 6 mg/kg Tiletamine/Zolazepam (Telazol) and maintained with 2% to 4% isoflurane for the duration of imaging procedures. Images were acquired using T2*-weighted spoiled gradient echo sequences with the following parameters: repetition time (TR)/effective echo time (TE), 30/11.3 ms; flip angle 5°; field of view (FOV) 19.2 mm²; matrix size 512 x 512; slice thickness 2 mm; receiver bandwidth 195 Hz/Px; acquisition time approximately 70 minutes.

2.4 | Mouse transplantation and MRI

Intracranial transplantation was performed on 16-week-old male C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine) using our established stereotactic approach. Briefly, mice were anesthetized with 2% isoflurane and placed in a standard Kopf stereotactic frame (David Kopf Instruments, Tujunga, California). hNSC suspensions were...
prepared at 30 k/μL in hibernation medium (Neuralstem, Inc.), and Trypan Blue exclusion ensured transplantation of >90% viable cells. hNSCs were delivered by bilateral injection to the fimbria of the hippocampus at three sites (3 × 1 μL hNSC-Mag+ left hemisphere and 3 × 1 μL unlabeled hNSCs contralateral; each administered over 60 seconds) at the following coordinates (bregma/lateral/ventral): −0.82/0.75/2.5, −1.46/2.3/2.9, −1.94/2.8/2.9 mm, totaling 90 k hNSCs per hemisphere per animal. All animals received immunosuppression of subcutaneous mycophenolate mofetil (30 mg/kg daily) until POD 7 and FK506 (3 mg/kg daily) for the study duration. MRI was performed on a GE-Agilent 9.4 Tesla horizontal bore system (GE Healthcare) at POD 7, 28, 42, and 70. Mice were anesthetized with 2% isoflurane and body temperature maintained at 37°C for the duration of imaging procedures. A quadrature volume radiofrequency coil was used to scan the head region of the mice. Axial T2*-weighted images were acquired using a gradient echo sequence with the following parameters: TR/TE 300/6 ms; flip angle 20; FOV 20 × 20 mm2; matrix size 256 × 128; slice thickness 0.5 mm; number of slices 25; acquisition time 2.5 minutes. All MR images were viewed and graft signal volumes calculated using ImageJ. Briefly, the ME contrast agent induces a susceptibility artifact on T2*-weighted images, so that hypointense signal can be regarded as the MRI correlate of hNSC-Mag+. Hypointense signal was measured in regions of interest containing labeled cell grafts and unlabeled control cell grafts. Any hypointense signal detected on the control side was used as a threshold to be exceeded on the contralateral side in order to be counted as signal derived from labeled cells. For each animal, the graft area was measured on each slice where the graft was visible (approximately 5-10 slices per animal), summed for all slices and subsequently multiplied by the slice thickness (0.5 mm). The presented data represent total graft area signal volume per animal per time point (mm3).

### 2.5 Tissue histology

The NHP was euthanized on POD 29, and the brain was harvested and processed for histology and immunohistochemistry as previously described. Briefly, the brain tissue was trimmed, cassetted, and fixed in 3.7% paraformaldehyde. Following standard paraffin processing, 4 μm sections were stained with H&E for injection site visualization or Perls’ Prussian Blue for iron detection. Immunostaining was performed using primary antibodies for STEM121 (Y40410, Takara, Mountain View, California), CD3 (RM9107, clone SP7, Fisher Scientific), CD68 (ab955, clone KP1, Abcam), GFAP (ab7260, Abcam), and Magnelles (Bell Biosystems). Subsets of mice were euthanized on POD 7, 28, and 70 (n = 3 per time point) directly after completion of MRI. Plasma FK506 was measured in peripheral blood obtained from the inferior vena cava. Mice were perfused with saline and 4% paraformaldehyde, and whole brains were postfixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and cryosectioned (coronal, 40 μm). Immunostaining was performed using primary antibodies for human nuclei (huNu; MAB1281, Millipore), Magnelles (Bell Biosystems), NeuN (ab104225, Abcam), GFAP (Z0334, Dako), hNestin (ABD69, Millipore), and Hoechst nuclear stain (Sigma; 5 mg/mL). Grafted hNSC were quantified in images captured from fimbria fornix target areas using the ImageJ multipoint tool (6 images/section; 10 sections/mouse). ME-derived iron was measured in the same regions using ImageJ, providing a composite measure of fluorescent intensity and area.

### 2.6 Statistics

Statistical significance was determined using Prism 8 (GraphPad Software Inc., La Jolla, California) and an α-level of .05. Brown-Forsythe F tests were used to compare variances and determine distribution. Data were analyzed by parametric t test, one-way analysis of variance (ANOVA) with Tukey’s post-test for comparisons of multiple groups, or Pearson’s correlation. In vitro data are presented as mean ± SEM or as representative images of at least three independent labeling experiments (n = 3-6 per condition). Sample size for in vivo experiments: NHP (n = 1) and mouse (n = 3 per POD time point).

### 3 RESULTS

#### 3.1 ME labeling, iron loading, and cell viability

To assess ME incorporation and postlabeling viability, hNSCs were initially labeled with ME labeling ratios (MLRs) of 2k, 4k, and 6k particles per cell. No differences in hNSC-Mag+ morphology were observed by bright field imaging and all groups appeared morphologically healthy (Figure 1A). ME incorporation was visualized using a Magnelle-specific antibody and tubulin to label cell borders. ME particles appeared punctate and localized to the perinuclear area of the cell (Figure 1B). No particles were found in unlabeled cell groups. Assessment of labeling efficiency revealed an average intracellular iron content that significantly increased with higher MLRs and ranged from 0.45 ± 0.12 pg/cell at 2 k MLR, to 0.82 ± 0.09 pg/cell at 6 k MLR (Figure 1C). At the tested MLRs, there were no significant differences in viability compared to controls, with >97% viability across all groups (Figure 1D).

#### 3.2 ME labeling does not impact hNSC functional properties in vitro

To assess biocompatibility, the basic cell functions of labeled hNSC-Mag+ with an iron content of 0.4 to 0.5 pg/cell were compared to unlabeled hNSC. Differentiation potential was maintained postlabeling, with similar expression patterns between labeled and unlabeled cells for markers of immature neurons (TUJ1+), mature neurons (MAP2+), astrocytes (GFAP+), and oligodendrocytes (OLIG2+) (Figure 2A). Migratory and proliferative capacity throughout differentiation was also maintained (Figure 2B,C). An important therapeutic feature of this hNSC line is the production of various secreted...
neurotrophic factors, including BDNF, IGF1, and VEGF. Here, quantified levels of secreted BDNF, IGF1, and VEGF were maintained throughout differentiation, with no significant changes measured postlabeling (Figure 2D-F). The impact of MEs on neuroprotective function was determined using an established toxicity assay in cortical neurons cocultured with or without hNSC. Apoptosis was significantly reduced when cocultured with hNSC or hNSC-Mag⁺ (cortical neurons alone, 64.9% ± 2.7%; hNSC, 14.6% ± 7.5%; hNSC-Mag⁺, 14.96% ± 3.1%; ANOVA; P < .05), indicating that neuroprotective capacity was unaffected by MEs (Figure 2G). Finally, the stability of ME labeling was determined in frozen stocks of hNSC-Mag⁺ and in hNSC-Mag⁺ cultured for 7 days, where intracellular iron was not significantly different from freshly labeled cells (data not shown). Collectively, these data demonstrate that ME particles are biocompatible with hNSCs,

**Figure 1** ME labeling of hNSCs. A, Brightfield imaging of unlabeled control hNSCs and ME-labeled hNSCs (hNSC-Mag⁺), with increasing MLR. Scale bar = 100 μm. B, Representative immunostaining showing ME localization (red) and tubulin cytoskeleton (green) in hNSC-Mag⁺ and control unlabeled hNSCs. Scale bar = 50 μm. C, Increased iron levels (Fe) with increasing MLR, *P < .05 (ANOVA). D, Viability measured by Trypan Blue dye exclusion. Data are presented as mean ± SEM or are representative images of at least three independent labeling experiments (n = 3-6 per condition). ANOVA, analysis of variance; hNSCs, human neural stem cells; ME, magneto-endosymbiont; MLR, ME loading ratio.
and that ME labeling resulting in an intracellular iron content of 0.4 to 0.5 pg/cell does not impact important therapeutic features of this cell line.

### 3.3 ME-enabled MRI tracking of hNSC in vivo

To assess the feasibility of ME-based tracking in a large animal model, intracranial transplantation was performed in a single NHP. hNSC-Mag+ were delivered to temporal, thalamus, and cingulate targets, and a single contralateral temporal targeted injection of unlabeled hNSC was performed as a control. T2*-weighted MRI was performed at various time points for 28 days after transplantation to identify ME-labeled transplanted cells (Figure 3). At POD 7, hNSC-Mag+ grafts were identified as hypointense MR signal at all three hNSC-Mag+ transplantation sites compared to the contralateral control injection site of unlabeled cells. By POD 14, the intensity of the left temporal and cingulate targets had decreased to that of the contralateral control site. The highest hypointense MR signal was observed at the thalamic target initially at POD 7, and, although there was a gradual decline over time, by POD 28 hypointense MR signal at this site was still increased compared to the control site and the hNSC-Mag+ temporal and cingulate sites.

We next further validated MRI tracking in mice, which enabled parallel evaluation of MR and tissue signal at multiple post-transplant...
time points. Intracranial transplantation was performed in C57BL/6J mice, with injection of 90 k hNSC-Mag+ and a contralateral internal control of 90 k unlabeled hNSC (Figure 4A), and serial T2*-weighted MRI tracking was used to follow cell grafts for up to 10 weeks post-transplantation (Figure 4B). At POD 7, hNSC-Mag+ grafts were detected as hypointense signal localized to the fimbria fornix target site in the hNSC-Mag+ hemisphere in all transplanted mice (n = 9 total). Negligible hypointense signal was observed at earlier time points on the contralateral side injected with control unlabeled cells, likely due to small areas of hemorrhage within injection tracts and tissue disruption at the surgical site. Quantification of MR signal for all mice and all time points (Figure 4C) revealed a variable signal volume at POD 7 that averaged 1.12 ± 0.2 mm³. By POD 28, the average signal volume was 0.88 ± 0.2 mm³, but this decrease was not significant.
**FIGURE 4** In vivo tracking of hNSC-Mag+ grafts in the mouse brain. A, Study design of hNSC-Mag+ transplantation via intracranial stereotaxic injection in mice, with contralateral internal controls of unlabeled hNSCs (fimbria fornix target site indicated by "+"). B, Representative serial T2* MRI sequence scans performed following transplantation on POD 7, 28, 42, 56, and 70; hNSC-Mag+ grafts visible as hypointense signal or dark contrast at the targeted fimbria fornix site (red circle); unlabeled cell grafts were not visualized (green circle). C, Graft volume calculated from hypointense signal in T2* MR images for all time points. Data are presented as representative MRI scans or mean ± SEM. Sample size of acquired MRI scans: POD 7 (n = 9), POD 28 (n = 6), POD 42 to 70 (n = 3). hNSCs, human neural stem cells; MRI, magnetic resonance imaging; POD, postoperative day.
(P = .462). In the subset of mice followed by serial MRI for 10 weeks (n = 3), initial average volumes were 1.35 ± 0.31 mm³ at POD 7, and gradually declined over the next 8 weeks (0.98 ± 0.14 mm³ at POD 56). By POD 70, signal volume was significantly reduced to 0.47 ± 0.09 mm³ (P < .05 vs POD 7, 28, 56).

3.4 | Postmortem histological validation of MR signal

Histological analysis of NHP brain tissue was performed 1 day after the final MRI on POD 29 (Figure 5). To explore whether the thalamic T2* hypointensity correlated with engrafted hNSCs, this site was analyzed in detail. Intact hNSCs were not detected morphologically or by immunostaining for human-specific STEM121 (Figure 5C,D). Injection sites were consistent with localized neuropil damage and phagocytosis of debris by activated macrophages. Infiltrating cells were composed primarily of macrophages (CD68+), with fewer T cells (CD3+), and a border of astrocytes (GFAP+) (Figure 5E-G). These areas were positive for iron and ME particles (Figure 5H,I). ME- and iron-containing debris within the extracellular space corresponded to the area of tissue damage and intracellular cytoplasmic staining corresponded to macrophages (CD68+ in serial sections), suggesting graft rejection and clearance by resident phagocytic macrophages. Postoperative monitoring of immunosuppressant FK506 levels in the NHP until endpoint indicated that target plasma levels within the range of 20 to 40 ng/mL were reached on POD 7; however, after this time point, levels dropped to <1 ng/mL due to variable success of oral PO dosing.

In mice, transplanted cell grafts were evaluated histologically at multiple time points, directly following MRI at POD 7, 28, and 70 (Figure 6). MR signal corresponded with huNu and ME immunostaining signal, most evident at the earlier time point where large grafts were visible, while contralateral control grafts exhibited huNu staining but no ME signal (Figure 6A,B). At high magnification, MEs colocalized with intact human cells (huNu+) and no ME staining was present on the contralateral control side (Figure 6C). Similar to in vitro immunostaining, ME particles appeared punctate and localized to the perinuclear area of the cell, indicating that ME labeling persists after in vivo transplantation. However, by the later terminal time points,
the grafts had reduced in size, demonstrated by diminished huNu and ME signal (Figure 6D-I). ME and huNu+ debris was observed in the target areas, indicative of graft rejection. Quantification showed a significant decline in huNu+ nuclei and ME signal over time, in line with MRI data (Figure 6J-L). A reduction of up to 80% occurred at POD 28 and POD 70, compared to the early time point ($P < .05$ vs POD 7). Linear correlations were observed between ME and MR signal ($r = 0.6964, P = .0372$), cell engraftment and MR signal ($r = 0.7059, P = .0336$), and ME and cell engraftment ($r = 0.7756, P = .0140$) (Figure 6M-O). Measurement of immunosuppressant FK506 levels at endpoint was below target range in the later cohorts despite evidence of target plasma levels of 20 to 40 ng/mL in POD 7 mice.

Mouse brain tissue was further analyzed across the terminal post-transplant time points to determine if ME labeling influences hNSC...
phenotype in vivo. No changes in cell distribution were observed between unlabeled hNSC and hNSC-Mag+ grafts (Figure 6B,D,F). Importantly, characterization of cell fate also indicated that ME labeling did not impact differentiation, as there were no changes in marker expression between hNSC-Mag+ and contralateral control hNSC grafts (Figure 7). At POD 7, hNSC and hNSC-Mag+ grafts expressed differentiation markers of early neural progenitor cells (human nestin+), but did not express markers of astrocytes or mature neurons (GFAP or NeuN). At the later POD 28 and 70 time points, no changes were observed between hNSC-Mag+ and contralateral control hNSC graft sites; however, grafts were significantly reduced, with few intact huNu+ cells visible within the injection tracts.

4 | DISCUSSION

Reliable and precise detection and tracking of transplanted cells is essential for understanding and advancing the field of stem cell therapies. In this study, we evaluated ME-based cell tracking in two immunocompetent xenotransplantation models and characterized the impact of labeling on neural cell function in vitro and in vivo. Our results show that hNSCs can be efficiently labeled with ME particles without affecting cell viability or other important in vitro functional properties. We also demonstrate, for the first time, MRI visualization and tracking of ME-labeled hNSCs in immunocompetent NHP and murine brain. In NHP brain, ME labeling enabled the detection of transplanted cells and their precise location by MRI, although engrafted hNSCs were not detected postmortem, consistent with diminished MR signal. In mice, MR signal was indicative of graft location and also correlated with postmortem tissue ME levels and engrafted hNSC nuclei. Unlike other iron-based labeling methods, the correlation between MR signal and cell engraftment suggests that with further optimization ME-based particles may be a useful method for determining graft rejection in vivo. Overall, these findings indicate that MEs are an effective tool for in vivo monitoring of cell-based therapies and may be easily applied to other cell lines and CNS diseases. Our use of a human cell product and two immunocompetent animal models, including a large animal model, make this report particularly relevant to translational pipelines and investigational new drug-enabling applications.

Our extensive in vitro characterization of ME-labeled hNSCs supports the contention that MEs are biocompatible. We showed that MEs are nontoxic to hNSCs, with no overt changes in survival, growth, or morphology. Importantly, ME labeling also did not alter therapeutically relevant cell functions, including production of secreted neurotrophic factors and neuroprotective capacity. MEs have previously been used to label 231BR, a human breast adenocarcinoma line, and human induced pluripotent stem cell (iPSC)-derived cardiomyocytes23,26; however, labeling efficiency is cell-type dependent and parameters require optimization on an individual basis. In this first report using MEs to label a neural cell type, we showed that hNSCs could be loaded with MEs with no detectable toxicity at any labeling ratio. Ideally, any modification or labeling for MRI contrast must not compromise the biological function of specific cell types. This safety aspect is critical to the translation of tracking technologies to clinical studies. Several reports indicate that SPIO labeling can negatively impact cell function. A deleterious dose-dependent effect on chondrogenesis was shown in mesenchymal stem cells33,34 and changes in neuronal and glial differentiation and migration were reported in neural precursors.19,35,36 Conversely, others have found no negative effect of SPIO or other magnetic nanoparticles on MRI TRACKING OF INTRACRANIAL STEM CELL GRAFTS

FIGURE 7 ME labeling does not impact in vivo phenotype of transplanted hNSC grafts. Representative immunostaining of hNSCs and hNSC-Mag+ grafts for NeuN, GFAP, and hNestin differentiation markers (red) with huNu (green) at terminal time points POD 7, 28, and 70. Images show regions of interest containing huNu+ grafts or injection tracts within the targeted fimbria fornix area, as indicated by dashed lines. Scale bar = 100 μm. Data are presented as representative images (n = 3 per POD time point). GFAP, glial fibrillary acidic protein; hNestin, human nestin; hNSCs, human neural stem cells; huNu, human nuclei; ME magneto-endosymbiont; NeuN, neuronal nuclei; POD, postoperative day.
growth, morphology, viability, or proliferation of neural progenitor cells, iPSC, and embryonic stem cells.\cite{12,20,37,39} Although not as well characterized as SPIO-based agents, ME labeling was previously shown to not impact the short-term cardiac properties of cardiomyocytes,\cite{23} suggesting that MEs are biocompatible. However, the impact of MEs on neural cell biology and functional properties had not yet been determined. We therefore assessed multiple aspects of cell function in a series of established assays.\cite{7,40} Contrary to findings that SPIO-based reagents disrupt normal differentiation patterns, we found that in vitro hNSC differentiation was unchanged by ME labeling. Similarly, proliferation, migration, production of neurotrophic growth factors BDNF, IGF1, and VEGF, and neuroprotective capacity were unchanged in undifferentiated and differentiated cell states. Collectively, these data demonstrate that MEs are biocompatible with this line of hNSCs and do not negatively impact important therapeutic features. Furthermore, we demonstrated the longevity and stability of ME labeling, where intracellular iron levels were retained after additional culturing and in frozen stocks, validating the use of hNSC-Mag\textsuperscript{+} for in vivo transplantation purposes.

Our transplantation studies in two animal models verify that ME labeling enables visualization and tracking of hNSCs in vivo by MRI. To our knowledge, this is the first report to demonstrate MRI tracking of transplanted human stem cells in the NHP brain. Transplanted hNSC-Mag\textsuperscript{+} were clearly identified in temporal, thalamus, and cingu- lature targets of the NHP brain by serial 3T MRI scans 1 week after transplantation, and up to 4 weeks postoperatively. Difficulty in administering PO immunosuppressant to this NHP resulted in insufficient plasma levels of FK506 after the first MRI scan. This, however, permitted correlation between MR signal and hNSC-Mag\textsuperscript{+} viability in a host with restored immune competency. Consequently, MR signal decreased over time, which was reflected in postmortem histological analysis showing minimal engraftment at 4 weeks post-transplant. At this point, no intact hNSCs were detected either morphologically or using human specific markers, despite extensive sectioning in the target areas. Immunohistochemistry profiling of the injection sites showed infiltrating immune cells and intracellular and extracellular staining for ME and iron particulates or remnants, suggesting that hNSC-Mag\textsuperscript{+} grafts were undergoing tissue clearance by phagocytic cells and perivascular flow. The observed decline in MR signal over time was therefore caused by transplanted cell death and clearance of ME particles. It is well established that immunosuppression is required to prevent rejection of allografts or xenografts in NHP.\cite{41,43} and these data are in line with multiple reports of poor engraftment and high rates of rejection of human cells after transplantation in other large animal models.\cite{19,44,45}

We further assessed ME tracking in a longitudinal study in rodents, which enabled postmortem tissue analysis and quantification in multiple animals at several post-transplant time points. This parallel study in mice validated our key findings in the NHP. On-target hNSCs were clearly identified in the fimbria fornix of all mice by 7T MRI. MR signal diminished over time and corresponded with histological hNSC-Mag\textsuperscript{+} grafts and ME particles. Engraftment was most robust at 1-week post-transplant, and ME particles were visible localized to intact hNSCs. Engraftment was reduced at the two later time points, consistent with the diminished MR signal. The linear correlations observed between MR signal, ME tissue signal, and cell engraftment suggest that with further optimization this approach may be useful for determining long-term graft survival or rejection in vivo. Sub- therapeutic FK506 levels are again a likely reason for graft rejection at later time points, and observed post-transplant cell survival is consistent with our ongoing studies and published reports in rodents.\cite{11,42,46}

In the literature, there is extensive evidence that residual extracellular or intramacrophagic iron from SPIO-based detection labels results in false MR signal long after transplanted cell death.\cite{15,24} This overestimation of cell survival limits the interpretation of long-term MRI tracking using such detection methods. SPIO particles have been detected extracellularly and within macrophages for months after transplanted cell death in myocardial infarction models.\cite{21,23,24} In rodent brain, particles persisted from 1 to 5 months with no correlating engraftment.\cite{14,15,20} Similarly, in minipig spinal cord, rejected cell grafts retained histologic iron, and MR signal also did not correlate with engraftment.\cite{19} Initial studies indicate that MEs clear from tissue more rapidly—reportedly within 1 week of cell death in the myocardium based on MR signal.\cite{23} This concept of live cell specificity unique to MEs has been associated with immune system interactions and is supported by previous studies using purified magnetosomes isolated from magnetotactic bacteria strains.\cite{47,49} In rats, magnetosomes were rapidly removed from the circulation via lysosomal digestion and clearance mediated by the reticuloendothelial system, also known as the mononuclear phagocyte system, comprised primarily of macrophages. ME antigenicity, relative to the inert coating of SPIO particles, combined with the release of proteins, nucleic acids, and polysaccharides after cell death, likely contribute to the targeting and clearance of magnetotactic bacteria and their associated magnetic particles by the immune system. However, the persistence of histological detection after cell death in the brain is unknown. Clearance likely depends on target tissue, vascularization, and activity of phagocytosing immune cells. Here, we observed a persistence of MR signal after transplanted cell death; however, unlike previous SPIO studies, there was a significant reduction in MR signal over time, which was detectable visually in NHP and by quantification of hypointense volume in mice. Moreover, in mice, histologic ME particles correlated with MR signal and engraftment, and by the later time points, ME particles were significantly reduced in rejected cell grafts. Thus, the over-estimation of cell survival due to persistence of labeling particles may not be as much of a problem with ME tracking as with SPIO-based methods.

This study has limitations. Our data showing ME biocompatibility and proof of concept ME-based in vivo tracking are limited to a single hNSC line that is currently under therapeutic development for Alzheimer’s disease as part of the NIA Alzheimer’s Drug Development Program (SU01AG057562). The feasibility of MEs as effective contrast agents must also be established for other cell types of interest, such as those derived from iPS or embryonic stem (ES) cells. Our data provide evidence of in vitro biocompatibility and establishes feasibility in vivo, but it was not possible to assess these parameters in vivo in the long term due to eventual graft rejection in immunocompetent...
To summarize, we report MEs as a useful preclinical tool for noninvasive MRI tracking of transplanted cells. Our results demonstrate their value as an in vivo indicator of graft location, volume, targeting accuracy, and engraftment. These data and currently available literature indicate that MEs are safe and fulfill many of the requirements of an ideal MRI contrast agent for cell tracking. However, additional long-term studies are needed to further develop the unique live-cell specificity feature for CNS applications. As cell-based therapies continue to progress through translational pipelines, the development of reliable technology to identify and monitor transplanted cells in vivo becomes increasingly important. A multimodal imaging strategy will most likely be used in future clinical settings to resolve current limitations of individual tracking techniques. The timely development of novel approaches such as this will undoubtedly advance the field of in vivo stem cell tracking and move us closer to developing effective treatments for patients with Alzheimer’s disease and other CNS disorders.

ACKNOWLEDGMENTS
This research was supported by the NIH (SU01AG057562-02, E.L.F., G.G.M., L.M.M.; RO1AG052934, G.G.M.; 1R43TR001202-01, C.B.B.; T32NS007222, M.S.W.; and R25NS089450, K.S.C.), the A. Alfred Taubman Medical Research Institute (P.G.P.), the Hileman Emerging Scholar Program (L.M.M.), the NeuroNetwork for Emerging Therapies, the Robert E. Niederlander Sr. Program for Alzheimer’s Research, and the Sinai Medical Staff Foundation. We thank Neuralstem, Inc. for supplying the hNSC line used in the study and Bell Biosystems, Inc. for supplying Magnelle tracking reagents, iron assay, and Magnelle antibody. We thank the Unit for Laboratory Animal Medicine, the in vivo Animal Core, Eric Kennedy, Paras Patel, Dina Salhani, and Ryan Smith at the University of Michigan for assistance with NHP care, surgical and MRI procedures, and histology. We are grateful to Dr Stephen I. Lentz and the Imaging Laboratory of the Microscopy, Imaging and Cellular Physiology Core of the Michigan Diabetes Research Center (funded by NIDDK under NIH5P60DK20572) for help with confocal imaging of whole brain sections, and the Department of Radiology at the University of Michigan for the use of the Center for Molecular Imaging and the Preclinical Imaging & Computational Analysis Shared Resource (supported in part by Comprehensive Cancer Center NIH Grant P30 CA046592). We are also thankful to Prof Sabine Heiland, PhD at the University Hospital Heidelberg for her guidance on MRI analysis.

CONFLICT OF INTEREST
E.L.F. is an unpaid consultant to Neuralstem, Inc., which owns patent rights to the hNSC line used in this study, is on an advisory board for Novartis, declared research funding from the National Institutes of Health (U01 AG057562-02). P.G.P. declared consultant/Advisory role with NeuroOne, Medtronic and stock interest in NeuroOne. C.B.B. was employed by Bell Biosystems, Inc., which supplied the patented Magnelle reagents, but was not involved in data acquisition or analysis. This company is no longer operational. J.K. declared advisory role Akcea Therapeutics, speaker honoraria, research and travel grant from Alnylam Pharmaceuticals. All other authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
L.M.M.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; M.S.W.: collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; O.N.K.: conception and design, collection and/or assembly of data, final approval of manuscript; K.S.C.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript; J.M.H., I.L.B., S.N.M., A.W.S., J.F.K., C.P.: collection and/or assembly of data, final approval of manuscript; J.K.: data analysis and interpretation, manuscript writing, final approval of manuscript; S.A.S.: manuscript writing, final approval of manuscript; C.B.B.: provision of study material, final approval of manuscript; C.A.C.: collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; G.G.M.: conception and design, final approval of manuscript; P.G.P.: conception and design, collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; E.L.F.: conception and design, financial support, final approval of manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Lisa M. McGinley https://orcid.org/0000-0003-0346-8242

REFERENCES
1. Garitaonandia I, Gonzalez R, Christiansen-Weber T, et al. Neural stem cell tumorigenicity and biodistribution assessment for phase I clinical trial in Parkinson’s disease. Sci Rep. 2016;6:34478.
2. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016;388(10046):787-796.
3. Kim HJ et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase 1 clinical trial. Alzheimers Dement. 2015;12(1):95-102.
4. Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke. 2016;47(7):1817-1824.
5. McGinley LM, Kashlan ON, Bruno ES, et al. Human neural stem cell transplantation improves cognition in a murine model of Alzheimer’s disease. Sci Rep. 2018;8(1):14776.
6. McGinley LM, Kashlam ON, Chen KS, et al. Human neural stem cell transplantation into the corpus callosum of Alzheimer’s mice. Ann Clin Transl Neurol. 2017;4(10):749-755.
7. McGinley LM, Sims E, Lunn JS, et al. Human cortical neural stem cells expressing insulin-like growth factor-I: a novel cellular therapy for Alzheimer’s disease. Stem Cells Translational Medicine. 2016;5:379-391.
8. Schweitzer JS, Song B, Harrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N Engl J Med. 2020;382(20):1926-1932.
9. Ager RR et al. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss. Hippocampus. 2015;25(7):813-826.
10. Bal P, Banik A, Nehru B, Anand A. Neurotrophic factors mediated activation of astrocytes ameliorate memory loss by amyloid clearance after transplantation of lineage negative stem cells. Mol Neurobiol. 2019;56:8420-8434.
11. Duncan T, Valenzuela M. Alzheimer’s disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017;8(1):111.
12. Lee IS, Jung K, Kim IS, et al. Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. Mol Neurodegener. 2015;10(1):38.
13. Bulte JW et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA. 1999;96(26):15256-15261.
14. Guzman R, Uchida N, Bliss TM, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci USA. 2007;104(24):10211-10216.
15. Berman SC, Galpouthawela C, Gilad AA, Bulte JWM, Walczak P. Long-term MR cell tracking of neural stem cells grafted in immuno-competent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells. Magn Reson Med. 2011;65(2):564-574.
16. Bernsen MR, Guenoun J, van Tiel ST, Krestit GP. Nanoparticles and clinically applicable cell tracking. Br J Radiol. 2015;88(1054):20150375.
17. Chromer Berman SM, Walczak P, Bulte JW. Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):343-355.
18. Cupaolo FA, Zucca FA, Boraschi D, Zecca L. Engineered nanoparticles. How brain friendly is this new guest? Prog Neurobiol. 2014;119-120:20-38.
19. Lamanna JJ, Gutierrez J, Uroquia LN, et al. Ferumoxylot labeling of human neural progenitor cells for diagnostic cellular tracking in the porcine spinal cord with magnetic resonance imaging. Stem Cells Translational Medicine. 2017;6(1):139-150.
20. Ramos-Gomez M, Seiz EG, Martinez-Serrano A. Optimization of the magnetic labeling of human neural stem cells and MRI visualization in the hemiparkinsonian rat brain. J Nanobiotechnology. 2015;13:20.
21. Chen IY, Greve JM, Gheyens O, et al. Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol Imaging Biol. 2009;11(3):178-187.
22. Kim JA, Åberg C, Salvari A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol. 2011;7(1):62-68.
23. Mahmoudi M, Tachibana A, Goldstone AB, et al. Novel MRI contrast agent from magnetotactic bacteria enables in vivo tracking of iPSC-derived cardiomyocytes. Sci Rep. 2016;6:26960.
24. Terrovitis J, Stuber M, Youssef A, et al. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation. 2008;117(12):1553-1562.
25. Bernau K, Lewis CM, Petelinska AM, et al. In vivo tracking of human neural progenitor cells in the rat brain using magnetic resonance imaging is not enhanced by ferritin expression. Cell Transplant. 2016;25(3):575-592.
26. Brewer KD, Spitzer R, Lee KR, et al. Characterization of magnetosensors as MRI cell labeling and tracking agents. Mol Imaging Biol. 2018;20(1):65-73.
27. Lee KR, Wakeel A, Chakraborty P, et al. Cell labeling with magnetosensors and the dissection of the subcellular location, fate, and host cell interactions. Mol Imaging Biol. 2018;20(1):55-64.
28. Komell A. Molecular mechanisms of compartmentalization and biominerallization in magnetotactic bacteria. FEMS Microbiol Rev. 2012;36(1):232-255.
29. Benoit MR, Mayer D, Barak Y, et al. Visualizing implanted tumors in mice with magnetic resonance imaging using magnetotactic bacteria. Cancer Res. 2009;15(16):5170-5177.
30. Bentley JN, Khalsa SSS, Kobylarek M, et al. A simple, inexpensive method for subcorical stereotactic targeting in nonhuman primates. J Neurosci Methods. 2018;305:89-97.
31. Saleem K, Logothetis N. A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates. 2nd ed. USA: Academic Press; 2012.
32. Glass JD, Hertberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392-400.
33. Kostura L, Krachtman DL, Mackay AM, Pittenger MF, Bulte JWM. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed. 2004;17(7):513-517.
34. Roeder E, Henrionnet C, Goebel JC, et al. Dose-response of superparamagnetic iron oxide labeling on mesenchymal stem cells chondrogenic differentiation: a multi-scale in vitro study. PLoS One. 2014;9(5):e98451.
35. Eamedgool SS, Weible MW II, Pham BTT, Hawkett BS, Grieve SM, Chan-ling T. Ultrasmall superparamagnetic iron oxide nanoparticle prelabelling of human neural precursor cells. Biomaterials. 2014;35(21):5549-5564.
36. Kallur T, Farr TD, Böhm-Sturm P, Kokaia Z, Hoehn M. Spatiotemporal dynamics, differentiation and viability of human neural stem cells after implantation into neonatal rat brain. Eur J Neurosci. 2011;34(3):382-393.
37. Parsa H, Shamsanjen K, Movassaghpour A, et al. Effect of superparamagnetic iron oxide nanoparticles-labeling on mouse embryonic stem cells. Cell J. 2015;17(2):221-230.
38. Ruan J, Shen J, Wang Z, et al. Efficient preparation and labeling of human induced pluripotent stem cells by nanotechnology. Int J Nanomedicine. 2011;6:425-435.
39. Shen WB, Placzel C, Chan A, et al. Human neural progenitor cells retain viability, phenotype, proliferation, and lineage differentiation when labeled with a novel iron oxide nanoparticle, Molday ION rhodamine B. Int J Nanomedicine. 2013;8:4593-4600.
40. Lunn JS et al. Autocrine production of IGF-I increases stem cell-mediated neuroprotection. Stem Cells. 2015;33(5):1480-1489.
41. Aron Badin R, Bugi A, Williams S, et al. MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates. Nat Commun. 2019;10(1):4357.

42. Diehl R, Ferrara F, Müller C, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol. 2017;14(2):146-179.

43. Morizane A, Doi D, Kikuchi T, et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013;1(4):283-292.

44. Gutierrez J et al. Preclinical validation of multilevel intraparenchymal stem cell therapy in the porcine spinal cord. Neurosurgery. 2015;77(4):604-612.

45. Pluchino S, Gritt A, Blezer E, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009;66(3):343-354.

46. Anderson AJ, Haus DL, Hooshmand MJ, Perez H, Sontag CJ, Cummings BJ. Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient? Regen Med. 2011;6(3):367-406.

47. Liu RT, Liu J, Tong JQ, et al. Heating effect and biocompatibility of bacterial magnetosomes as potential materials used in magnetic fluid hyperthermia. Prog Nat Sci Mater Int. 2012;22(1):31-39.

48. Sun J, Tang T, Duan J, et al. Biocompatibility of bacterial magnetosomes: acute toxicity, immunotoxicity and cytotoxicity. Nanotoxicology. 2010;4(3):271-283.

49. Sun JB, Wang ZL, Duan JH, et al. Targeted distribution of bacterial magnetosomes isolated from Magnetospirillum gryphiswaldense MSR-1 in healthy Sprague-Dawley rats. J Nanosci Nanotechnol. 2009;9(3):1881-1885.

How to cite this article: McGinley LM, Willsey MS, Kashlan ON, et al. Magnetic resonance imaging of human neural stem cells in rodent and primate brain. STEM CELLS Transl Med. 2021;10:83–97. https://doi.org/10.1002/sctm.20-0126